When combined treatment is not possible or after the failure of BRAF and MEK inhibitors in BRAF-mutated melanomas, approximately 75% of patients treated with monotherapy with iPD-1 undergo progression within 5 years [2]. The gene discussed is MAP2K7; the disease is melanoma.